The pilot project ‘Chemical recycling of plastics from automobile construction’ is being led by the Thinktank Industrial Resource Strategies at the Karlsruhe Institute of Technology (KIT) and the car major Audi. The project aims to use waste from engineering plastics and process it into pyrolysis oil in order to create new components.

The Louisiana-based integrated polyethylene joint venture transaction has been successfully completed by Lyondell Basell and Sasol. Under the terms of the agreement, Lyondell Basell will operate the assets owned by the JV and also market the polyethylene products on behalf of the JV.

With the new oil-free DSS scroll vacuum pump, Atlas Copco is expanding its range of dry industrial pumps. The robust, low-wear pump is particularly suitable for vacuum generation in the rough vacuum range.

On December 17, the U.S. Food and Drug Administration (U.S. FDA) has plans to conduct an advisory committee meeting in order to discuss the emergency use authorisation (EUA) for Moderna’s Covid-19 vaccine.

Under a joint venture agreement signed between Thermo Fisher Scientific and Innoforce, both the companies will work together to establish a biologics and steriles drug development and manufacturing facility in Hangzhou, China.

BASF’s new plant has been developed in Pontecchio Marconi, Italy and will offer its Nor technology platform to the expanding agriculture industry. The platform comprises of a range of light and thermal stabilisers which prove beneficial for plasticulture applications.

Under a strategic partnership signed between Royal DSM and Neste, DSM will help Neste to create high-performance sustainable polymers in order to reduce the carbon footprints of its own products and also support the circular economy transition.

The UK has become the first country in the world to approve a Covid-19 vaccine in order to combat the global pandemic. The first doses of the vaccine developed by Pfizer-Biontech will be available to the UK immediately.

CPhI’s new report predicts a positive outlook for the pharma manufacturing supply chain in 2021 and highlights that the most immediate trend will be to witness some degree of ‘vaccine nationalism’ in the background of the initial stage of global Covid-19 vaccines roll-out before scale-up is achieved.

Clariant is in the process of transforming its portfolio into a higher-value specialty one by focusing on its core business areas – Care Chemicals, Catalysis and Natural Resources. The company will also rightsize its regional organisations and service units in order to avoid remnant cost.